

Caroline A Heckman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4466382/publications.pdf>

Version: 2024-02-01

139
papers

4,703
citations

172457
29
h-index

106344
65
g-index

147
all docs

147
docs citations

147
times ranked

8211
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Somatic <i>STAT3</i> Mutations in Large Granular Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2012, 366, 1905-1913. | 27.0 | 681 |
| 2 | Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2013, 3, 1416-1429. | 9.4 | 334 |
| 3 | Functional interaction of VEGF β and VEGF α with neuropilin receptors. <i>FASEB Journal</i> , 2006, 20, 1462-1472. | 0.5 | 265 |
| 4 | Discovery of somatic <i>STAT5b</i> mutations in large granular lymphocytic leukemia. <i>Blood</i> , 2013, 121, 4541-4550. | 1.4 | 252 |
| 5 | Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. <i>Scientific Reports</i> , 2014, 4, 5193. | 3.3 | 243 |
| 6 | Comparison of solution-based exome capture methods for next generation sequencing. <i>Genome Biology</i> , 2011, 12, R94. | 9.6 | 237 |
| 7 | Histone Deacetylase Inhibitors Down-Regulate <i>bcl-2</i> Expression and Induce Apoptosis in t(14;18) Lymphomas. <i>Molecular and Cellular Biology</i> , 2005, 25, 1608-1619. | 2.3 | 227 |
| 8 | Negative regulation of <i>bcl-2</i> expression by p53 in hematopoietic cells. <i>Oncogene</i> , 2001, 20, 240-251. | 5.9 | 200 |
| 9 | NF- κ B activates <i>Bcl-2</i> expression in t(14;18) lymphoma cells. <i>Oncogene</i> , 2002, 21, 3898-3908. | 5.9 | 174 |
| 10 | Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 1062-1069. | 2.8 | 172 |
| 11 | Immunogenomic Landscape of Hematological Malignancies. <i>Cancer Cell</i> , 2020, 38, 380-399.e13. | 16.8 | 109 |
| 12 | Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer. <i>PLoS Computational Biology</i> , 2019, 15, e1006752. | 3.2 | 106 |
| 13 | The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis. <i>Cancer Research</i> , 2008, 68, 4754-4762. | 0.9 | 104 |
| 14 | Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, 708-720. | 3.5 | 99 |
| 15 | MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. <i>Journal of Hematology and Oncology</i> , 2020, 13, 173. | 17.0 | 91 |
| 16 | JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. <i>Blood</i> , 2017, 130, 789-802. | 1.4 | 90 |
| 17 | Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 319-327. | 1.9 | 74 |
| 18 | Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2022, 12, 388-401. | 9.4 | 73 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | The WT1 Protein Is a Negative Regulator of the Normal bcl-2 Allele in t(14;18) Lymphomas. Journal of Biological Chemistry, 1997, 272, 19609-19614. | 3.4 | 70 |
| 20 | Making Sense of the Epigenome Using Data Integration Approaches. Frontiers in Pharmacology, 2019, 10, 126. | 3.5 | 58 |
| 21 | A-Myb Up-regulates Bcl-2 through a Cdx Binding Site in t(14;18) Lymphoma Cells. Journal of Biological Chemistry, 2000, 275, 6499-6508. | 3.4 | 53 |
| 22 | CCAAT/Enhancer Binding Protein β (C/EBP β) and C/EBP β Myeloid Oncoproteins Induce Bcl-2 via Interaction of Their Basic Regions with Nuclear Factor- κ B p50. Molecular Cancer Research, 2005, 3, 585-596. | 3.4 | 50 |
| 23 | The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia. BMC Genomics, 2017, 18, 629. | 2.8 | 42 |
| 24 | Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia. Leukemia, 2019, 33, 1360-1372. | 7.2 | 40 |
| 25 | Regulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells. Oncogene, 2003, 22, 7891-7899. | 5.9 | 39 |
| 26 | Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting. Oncogene, 2019, 38, 3288-3300. | 5.9 | 39 |
| 27 | Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. Blood Advances, 2020, 4, 546-559. | 5.2 | 36 |
| 28 | Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets. Leukemia, 2020, 35, 1964-1975. | 7.2 | 35 |
| 29 | Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing. Oncotarget, 2017, 8, 56338-56350. | 1.8 | 35 |
| 30 | RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses. Leukemia, 2021, 35, 1087-1099. | 7.2 | 32 |
| 31 | Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melphalen. Cancers, 2021, 13, 1527. | 3.7 | 29 |
| 32 | Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. Science Advances, 2021, 7, . | 10.3 | 28 |
| 33 | Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. Oncotarget, 2017, 8, 97516-97527. | 1.8 | 28 |
| 34 | Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma. Blood Advances, 2017, 1, 2257-2268. | 5.2 | 25 |
| 35 | Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML. Leukemia, 2019, 33, 2548-2553. | 7.2 | 25 |
| 36 | Germline alterations in a consecutive series of acute myeloid leukemia. Leukemia, 2018, 32, 2282-2285. | 7.2 | 24 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | A Multiplexed Screening Assay to Evaluate Chemotherapy-Induced Myelosuppression Using Healthy Peripheral Blood and Bone Marrow. <i>SLAS Discovery</i> , 2018, 23, 687-696. | 2.7 | 23 |
| 38 | Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies. <i>Cancer Research</i> , 2019, 79, 2466-2479. | 0.9 | 23 |
| 39 | Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition. <i>Leukemia</i> , 2020, 34, 3186-3196. | 7.2 | 22 |
| 40 | Critical elements of the immunoglobulin heavy chain gene enhancers for deregulated expression of bcl-2. <i>Cancer Research</i> , 2003, 63, 6666-73. | 0.9 | 22 |
| 41 | Somatic MED12 Nonsense Mutation Escapes mRNA Decay and Reveals a Motif Required for Nuclear Entry. <i>Human Mutation</i> , 2017, 38, 269-274. | 2.5 | 20 |
| 42 | Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types. <i>Haematologica</i> , 2020, 105, 1527-1538. | 3.5 | 19 |
| 43 | The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains. <i>Oncotarget</i> , 2017, 8, 103731-103743. | 1.8 | 19 |
| 44 | Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2022, 140, 1891-1906. | 1.4 | 19 |
| 45 | Combined gene essentiality scoring improves the prediction of cancer dependency maps. <i>EBioMedicine</i> , 2019, 50, 67-80. | 6.1 | 18 |
| 46 | Prognostic significance of esterase gene expression in multiple myeloma. <i>British Journal of Cancer</i> , 2021, 124, 1428-1436. | 6.4 | 18 |
| 47 | Phosphoprotein profiling predicts response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients. <i>Experimental Hematology</i> , 2012, 40, 705-714.e3. | 0.4 | 16 |
| 48 | Bipartite network models to design combination therapies in acute myeloid leukaemia. <i>Nature Communications</i> , 2022, 13, 2128. | 12.8 | 15 |
| 49 | Targeting of JAK/STAT Signaling to Reverse Stroma-Induced Cytoprotection Against BCL2 Antagonist Venetoclax in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 32-32. | 1.4 | 14 |
| 50 | Chemical, Physical and Biological Triggers of Evolutionary Conserved Bcl-xL-Mediated Apoptosis. <i>Cancers</i> , 2020, 12, 1694. | 3.7 | 13 |
| 51 | Fusion gene detection by RNA sequencing complements diagnostics of acute myeloid leukemia and identifies recurring NR1P1-MIR99AHG rearrangements. <i>Haematologica</i> , 2021, , . | 3.5 | 13 |
| 52 | Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. <i>Oncotarget</i> , 2017, 8, 22606-22615. | 1.8 | 13 |
| 53 | Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. <i>Npj Precision Oncology</i> , 2021, 5, 71. | 5.4 | 12 |
| 54 | Endogenous and combination retinoids are active in myelomonocytic leukemias. <i>Haematologica</i> , 2021, 106, 1008-1021. | 3.5 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Statistical detection of quantitative protein biomarkers provides insights into signaling networks deregulated in acute myeloid leukemia. <i>Proteomics</i> , 2014, 14, 2443-2453. | 2.2 | 10 |
| 56 | C/EBP β and C/EBP δ Myeloid Oncoproteins Induce Bcl-2 Via Interaction of Their Basic Regions with NF- κ B p50. <i>Blood</i> , 2005, 106, 2992-2992. | 1.4 | 10 |
| 57 | Allelic Imbalance of Recurrently Mutated Genes in Acute Myeloid Leukaemia. <i>Scientific Reports</i> , 2019, 9, 11796. | 3.3 | 9 |
| 58 | Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients. <i>Scientific Reports</i> , 2021, 11, 12866. | 3.3 | 8 |
| 59 | CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemia. <i>Science Translational Medicine</i> , 2022, 14, . | 12.4 | 8 |
| 60 | Functional Analysis of FLT4 Mutations Associated with Nonneâ€™Milroy Lymphedema. <i>Journal of Investigative Dermatology</i> , 2009, 129, 509-512. | 0.7 | 7 |
| 61 | Improving genomics-based predictions for precision medicine through active elicitation of expert knowledge. <i>Bioinformatics</i> , 2018, 34, i395-i403. | 4.1 | 6 |
| 62 | KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2780-2784. | 7.2 | 6 |
| 63 | Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 4125-4139. | 5.2 | 6 |
| 64 | RUNX1 Mutations Identify an Entity of Blast Phase Chronic Myeloid Leukemia (BP-CML) Patients with Distinct Phenotype, Transcriptional Profile and Drug Vulnerabilities. <i>Blood</i> , 2018, 132, 4257-4257. | 1.4 | 6 |
| 65 | Recurrent Missense Mutations in the STAT3 Gene in LGL Leukemia Provide Insights to Pathogenetic Mechanisms and Suggest Potential Diagnostic and Therapeutic Applications. <i>Blood</i> , 2011, 118, 936-936. | 1.4 | 6 |
| 66 | Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches. <i>Proteomes</i> , 2021, 9, 42. | 3.5 | 6 |
| 67 | FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML. <i>Scientific Reports</i> , 2021, 11, 23565. | 3.3 | 6 |
| 68 | Allele-specific analysis of transcription factors binding to promoter regions. <i>Methods</i> , 2002, 26, 19-26. | 3.8 | 5 |
| 69 | Chimeric NUP98â€™NSD1 transcripts from the cryptic t(5;11)(q35.2;p15.4) in adult de novo acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 725-732. | 1.3 | 5 |
| 70 | Comparison of Structural and Short Variants Detected by Linked-Read and Whole-Exome Sequencing in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 1212. | 3.7 | 5 |
| 71 | S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 723016. | 3.7 | 5 |
| 72 | Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types. <i>Blood</i> , 2018, 132, 264-264. | 1.4 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Novel Activating STAT5B Mutations As Drivers Of T-ALL. Blood, 2013, 122, 3863-3863. | 1.4 | 5 |
| 74 | Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia. HemaSphere, 2022, 6, e701. | 2.7 | 4 |
| 75 | The Use of RNA Sequencing to Identify Disease-Specific Gene Expression Signatures and Critical Regulatory Networks Across Hematologic Malignancies. Blood, 2014, 124, 2203-2203. | 1.4 | 3 |
| 76 | Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma. Blood, 2014, 124, 2046-2046. | 1.4 | 3 |
| 77 | The Peptideâ€“Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death. HemaSphere, 2022, 6, e687. | 2.7 | 3 |
| 78 | Review: Aminopeptidases in Cancer, Biology and Prospects for Pharmacological Intervention. Current Cancer Drug Targets, 2022, 22, . | 1.6 | 3 |
| 79 | Enrichment of cancer-predisposing germline variants in adult and pediatric patients with acute lymphoblastic leukemia. Scientific Reports, 2022, 12, . | 3.3 | 3 |
| 80 | Paradox-Breaker Pan-RAF Inhibitors Induce an AML-Specific Cytotoxic Response and Synergize with Venetoclax to Display Superior Antileukemic Activity. Blood, 2018, 132, 2210-2210. | 1.4 | 2 |
| 81 | Predictive Response Biomarkers for BET Inhibitors in AML. Blood, 2018, 132, 2749-2749. | 1.4 | 2 |
| 82 | Combined Targeting of BET Family Proteins and BCL2 Is Synergistic in Acute Myeloid Leukemia Cells Overexpressing S100A8 and S100A9. Blood, 2018, 132, 2634-2634. | 1.4 | 2 |
| 83 | In Vitro and inVivo Activity of Melflufen in Amyloidosis. Blood, 2019, 134, 3100-3100. | 1.4 | 2 |
| 84 | Discovery of STAT5b Mutations and Small Subclones of STAT3 Mutations in Large Granular Lymphocytic (LGL) Leukemia. Blood, 2012, 120, 871-871. | 1.4 | 2 |
| 85 | Preclinical Activity of Selective SYK Inhibitors, Entospletinib and Lanraplenib, Alone or Combined with Targeted Agents in Ex Vivo AML Models with Diverse Mutational Backgrounds. Blood, 2021, 138, 3356-3356. | 1.4 | 2 |
| 86 | Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation. Blood, 2021, 138, 4041-4041. | 1.4 | 2 |
| 87 | Phosphoproteomic Analysis of Primary Myeloma Patient Samples Identifies Distinct Phosphorylation Signatures Correlating with Chemo-Sensitivity Profiles in an Ex Vivo Drug Sensitivity Testing Platform. Blood, 2021, 138, 2666-2666. | 1.4 | 2 |
| 88 | Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen. Cells, 2022, 11, 1574. | 4.1 | 2 |
| 89 | A candid view of CANDOR. Lancet, The, 2020, 396, 147-148. | 13.7 | 1 |
| 90 | Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML. Blood, 2018, 132, 2763-2763. | 1.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | A Phase 2 Study of Carfilzomib Plus Elotuzumab Plus Dexamethasone for Myeloma Patients Relapsed after 1-3 Prior Treatment Lines. Blood, 2018, 132, 1975-1975. | 1.4 | 1 |
| 92 | Landscape of Mutations in Relapsed Acute Myeloid Leukemia. Blood, 2014, 124, 2367-2367. | 1.4 | 1 |
| 93 | Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles. Blood, 2017, 130, 854-854. | 1.4 | 1 |
| 94 | High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML. Blood, 2012, 120, 288-288. | 1.4 | 1 |
| 95 | AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex Vivo Patient Cells with in Vitro Cell Lines. Blood, 2014, 124, 2163-2163. | 1.4 | 1 |
| 96 | Ex Vivo Drug Sensitivity Testing to Predict Response to Venetoclax + Azacitidine in Acute Myeloid Leukemia: Interim Results of the Prospective Multicenter Phase II Venex Trial. Blood, 2021, 138, 228-228. | 1.4 | 1 |
| 97 | Stromal-Derived Factors Modulate Ex Vivo Drug Responses of Primary Acute Myeloid Leukemia Cells. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S8-S9. | 0.4 | 0 |
| 98 | Case studies investigating genetic heterogeneity between anatomically distinct bone marrow compartments in acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 3002-3005. | 1.3 | 0 |
| 99 | Next Generation Proteomics and Drug Sensitivity Resistance Testing Allow for the Identification of Distinct Sub-clones of Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e102. | 0.4 | 0 |
| 100 | A phase 2 study of carfilzomib plus elotuzumab plus dexamethasone for myeloma patients relapsed after 1-3 prior treatment lines. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e279-e280. | 0.4 | 0 |
| 101 | HDAC2 Plays a Role in Protecting t(14;18) Lymphoma Cells from Apoptosis by Up-Regulation of Bcl-2.. Blood, 2004, 104, 1133-1133. | 1.4 | 0 |
| 102 | C/EBP β and C/EBP δ Myeloid Oncoproteins Inhibit Apoptosis and Induce Bcl-2 Via DNA-Binding Dependent and Independent Mechanisms.. Blood, 2004, 104, 2561-2561. | 1.4 | 0 |
| 103 | Molecular Targeting of Lymphangiogenesis and Tumor Metastasis. , 2009, , 283-295. | | 0 |
| 104 | Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib. Blood, 2011, 118, 2487-2487. | 1.4 | 0 |
| 105 | Phosphoprotein Profiling Predicts Response to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients. Blood, 2011, 118, 4427-4427. | 1.4 | 0 |
| 106 | Somatic PTPRT and ANGPT2 Mutations in Large Granulocyte Leukemia. Blood, 2012, 120, 1302-1302. | 1.4 | 0 |
| 107 | Stromal Cell Supported High-Throughput Drug Testing Of Primary Leukemia Cells For Comprehensive Assessment Of Sensitivity To Novel Therapies. Blood, 2013, 122, 1668-1668. | 1.4 | 0 |
| 108 | Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex Vivo Drug Testing. Blood, 2013, 122, 3828-3828. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling. Blood, 2013, 122, 482-482. | 1.4 | 0 |
| 110 | High-Throughput Drug Sensitivity and Resistance Testing (DSRT) Platform Reveals Novel Candidate Drugs For Advanced Phase BCR-ABL1-Positive Leukemia. Blood, 2013, 122, 2719-2719. | 1.4 | 0 |
| 111 | Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling. Blood, 2014, 124, 917-917. | 1.4 | 0 |
| 112 | Identification of Novel Therapeutic Strategies for NUP98-NSD1-Positive AML By Drug Sensitivity Profiling. Blood, 2014, 124, 2160-2160. | 1.4 | 0 |
| 113 | Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing. Blood, 2014, 124, 3505-3505. | 1.4 | 0 |
| 114 | Identification of Dual PI3K/mTOR and BCL2 Inhibitors for the Treatment of High Risk Multiple Myeloma. Blood, 2014, 124, 646-646. | 1.4 | 0 |
| 115 | Analysis of Clonal Evolution in Chemorefractory Acute Myeloid Leukemia from Diagnosis to Relapse. Blood, 2014, 124, 1022-1022. | 1.4 | 0 |
| 116 | Drug Sensitivity Profiling Identifies Drugs for Targeting Constitutively Active Mutant STAT3 and Mutant STAT5B Positive Malignancies. Blood, 2014, 124, 1771-1771. | 1.4 | 0 |
| 117 | A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses. Blood, 2014, 124, 3139-3139. | 1.4 | 0 |
| 118 | Landscape of Driver Lesions in Multiple Myeloma and Consequences for Targeted Drug Response. Blood, 2014, 124, 3351-3351. | 1.4 | 0 |
| 119 | Stratification of Multiple Myeloma Patients Based on Ex Vivo Drug Sensitivity and Identification of New Treatments for Patients with High-Risk Relapsed/Refractory Disease. Blood, 2015, 126, 3006-3006. | 1.4 | 0 |
| 120 | BCL2-Inhibitors Target a Major Group of Newly-Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo. Blood, 2015, 126, 2462-2462. | 1.4 | 0 |
| 121 | JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML. Blood, 2015, 126, 867-867. | 1.4 | 0 |
| 122 | In Silico and Ex Vivo Drug Screening Identifies Dasatinib as a Potential Targeted Therapy for T-ALL. Blood, 2016, 128, 4029-4029. | 1.4 | 0 |
| 123 | Identification of Optimized Compound Combinations for the Treatment of NUP98-NSD1+ AML. Blood, 2016, 128, 4711-4711. | 1.4 | 0 |
| 124 | Simultaneous Monitoring of Drug Responses on Distinct Hematopoietic Cell Populations Allow Assessment of Direct and Indirect Cytotoxic Effects of Targeted Therapies. Blood, 2016, 128, 3515-3515. | 1.4 | 0 |
| 125 | A High-Throughput Biology Approach to Identify Novel Therapies Specifically Targeting AML Blasts and Leukemic Stem Cells. Blood, 2016, 128, 2755-2755. | 1.4 | 0 |
| 126 | Novel Mutations in Patients with Blast Crisis or Accelerated Phase Chronic Myeloid Leukemia. Blood, 2016, 128, 1924-1924. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Transcriptional Regulatory Landscape of TCF3-PBX1-Positive Leukemia and Novel Targeted Treatments. Blood, 2016, 128, 4077-4077. | 1.4 | 0 |
| 128 | DNA Damage Repair Pathway Alterations in Multiple Myeloma Predict Poor Prognosis, but Correlate with Sensitivity to IGF1R-PI3K-mTOR and HDAC Inhibitors. Blood, 2016, 128, 198-198. | 1.4 | 0 |
| 129 | Combining Next Generation Proteomics Platforms with Drug Sensitivity Resistance Testing Allows Identification of Physiologically Distinct Sub-Clones, That Can Inform Therapeutic and Drug Development Strategies. Blood, 2018, 132, 1901-1901. | 1.4 | 0 |
| 130 | Eltrombopag Promotes Megakaryocyte Survival and Signaling in the Presence of Specific Cytotoxic Agents. Blood, 2018, 132, 3836-3836. | 1.4 | 0 |
| 131 | Targeting BCL-2, BCL-XL, BCL-W and MDM2 in B-Cell Acute Lymphoblastic Leukemia Is Highly Effective Ex Vivo. Blood, 2018, 132, 3975-3975. | 1.4 | 0 |
| 132 | Associations between Microrna Expression, Disease Progression and Ex Vivo Drug Response in Multiple Myeloma. Blood, 2019, 134, 3069-3069. | 1.4 | 0 |
| 133 | Germline Gene Aberrations Are Common in High-Risk Adult and Pediatric Acute Lymphoblastic Leukemia Patients. Blood, 2019, 134, 1472-1472. | 1.4 | 0 |
| 134 | Azacytidine Inhibits Megakaryopoiesis Via the Induction of Immunogenic RNA Species and Activation of Type-I Interferon Signaling. Blood, 2019, 134, 1280-1280. | 1.4 | 0 |
| 135 | Deep Immune Profiling in Multiple Myeloma at Diagnosis and Under Lenalidomide Maintenance Therapy. Blood, 2021, 138, 1597-1597. | 1.4 | 0 |
| 136 | Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database. Blood, 2021, 138, 608-608. | 1.4 | 0 |
| 137 | Single Cell RNA Sequencing Identifies Potential Molecular Indicators of Response to Melflufen in Multiple Myeloma. Blood, 2021, 138, 1194-1194. | 1.4 | 0 |
| 138 | Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study. Blood, 2021, 138, 3438-3438. | 1.4 | 0 |
| 139 | Integration of Deep Multi-Omics Profiling Veals New Insights into the Biology of Poor-Risk Acute Myeloid Leukemia. Blood, 2020, 136, 39-40. | 1.4 | 0 |